Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Delisting risk
confidence 95%
filed 2026-05-27
Snail, Inc. received a deficiency letter from Nasdaq on March 26, 2026, for failing to meet the Net Income Requirement and alternative continued listing standards (market value of listed securities and stockholders' equity). The company submitted a Compliance Plan and received an Extension Letter on May 20, 2026, granting until September 22, 2026, to regain compliance, with explicit warning that failure to comply upon filing the Q3 2026 quarterly report will result in delisting of Class A Common Stock. This is a clear delisting risk disclosure under Item 8.01.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-27
The filing discloses Greenwave's receipt of a delinquency notification from Nasdaq on May 21, 2026, due to failure to timely file its Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Item 3.01 explicitly addresses "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard," and the Company has until June 22, 2026 to submit a compliance plan or face potential delisting. This is a material event that directly threatens the Company's continued listing on Nasdaq Capital Market.
View raw filing on EDGAR →
Delisting risk
confidence 72%
filed 2026-05-27
Item 8.01
BuzzFeed regained compliance with Nasdaq's $1.00 minimum bid price requirement, resolving a deficiency notice received on March 2, 2026, and eliminating delisting risk.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-27
Item 3.01
Flag Ship Acquisition Corp received a deficiency notice from Nasdaq for failure to timely file Form 10-K and Form 10-Q, triggering non-compliance with Nasdaq Listing Rule 5250(c)(1). The Company has 60 days to submit a compliance plan and faces potential delisting if it cannot regain compliance by October 12, 2026.
View raw filing on EDGAR →
Delisting risk
confidence 92%
filed 2026-05-26
Item 8.01
The filing discloses that Cypherpunk Technologies received a Nasdaq deficiency notice on March 4, 2026 for failing to maintain the minimum $1.00 bid price requirement for 30 consecutive business days, triggering delisting risk under Nasdaq Listing Rule 5550(a)(2). Although the company subsequently regained compliance by May 21, 2026, the disclosure of the initial deficiency notice and the cure period is a material delisting-risk event that would affect investor assessment of listing status and financial condition.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-26
Item 3.01
Columbus Acquisition Corp received written notice from Nasdaq on May 22, 2026, that it failed to comply with two continued listing criteria: the Minimum Holders Rule (requiring 400+ holders) and the Market Value of Listed Securities Rule (requiring $50 million MVLS). While the notices are characterized as deficiency notifications rather than imminent delisting, the Company faces a 45-day deadline to submit a compliance plan for the Minimum Holders Rule and a 180-day compliance period for the MVLS Rule, with explicit warning that failure to regain compliance will result in delisting notification. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 92%
filed 2026-05-26
Item 3.01
Evolution Metals & Technologies Corp. received a notice from Nasdaq on May 21, 2026, that it failed to comply with Nasdaq Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for the period ended March 31, 2026. Although the Company cured the deficiency by filing the Form 10-Q on May 22, 2026, and regained compliance by May 26, 2026, the initial notice of non-compliance with a continued listing rule constitutes a material delisting risk event.
View raw filing on EDGAR →
Delisting risk
confidence 75%
filed 2026-05-26
The filing discloses two material events: (1) a private placement of 500,000 shares for $500,000 (Item 1.01, 3.02), and (2) a Nasdaq deficiency letter on May 26, 2026 notifying the Company it failed to maintain the minimum $2.5 million stockholders' equity requirement under Listing Rule 5550(b)(1) (Item 3.01). While the private placement itself is a dilutive issuance, the delisting risk is the more material and time-sensitive disclosure—the Company has 45 days to submit a compliance plan or face potential delisting. The deficiency letter represents a direct threat to continued listing and would materially affect investor assessment of the registrant's viability.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-26
Item 3.01 discloses that Vestand Inc. received a Staff Delisting Determination from Nasdaq on May 19, 2026, initiating a process that could result in delisting of the Company's Class A Common Stock due to failure to file delinquent quarterly and annual reports (September 2025 10-Q, 2025 10-K, and March 2026 10-Q). The filing explicitly states that if the Company's requests for stay and extension are not granted, "the Company's shares of Class A Common Stock will be delisted from the Nasdaq stock exchange." This is a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-26
Item 3.01
The filing discloses a delisting notice and subsequent cure. The Company received a November 2025 notice from Nasdaq that it failed to comply with Listing Rule 5550(b) minimum standards (stockholders' equity, market value, or net income), but on May 20, 2026, Nasdaq notified the Company that it has returned to compliance with continued listing requirements. This is a material delisting-risk event that directly affects the registrant's ability to maintain its listing status.
View raw filing on EDGAR →
Delisting risk
confidence 97%
filed 2026-05-26
Item 3.01
Nuvve received written notice from Nasdaq on May 22, 2026, that it failed to comply with Listing Rule 5250(c)(1) by not filing its Form 10-Q for the period ended March 31, 2026. This notice serves as an additional basis for delisting, compounding the Company's existing delisting risk from its stock price falling below $1.00 per share for 30 consecutive trading days, and the Company is currently before the Nasdaq Hearings Panel.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-22
Item 3.01
TransCode Therapeutics received a deficiency letter from Nasdaq on May 19, 2026, notifying the company that it failed to maintain the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market, with reported stockholders' equity of only $1,251,427 as of March 31, 2026. The company has 45 days to submit a compliance plan, and failure to regain compliance could result in delisting. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-22
Item 3.01
DevvStream Corp. disclosed multiple delisting risks under Item 3.01: failure to comply with Nasdaq Listing Rule 5550(b) (Net Income Requirement of $500,000 minimum) and Nasdaq Listing Rule 5450(a)(1) (Minimum Bid Price Rule of $1.00 per share). The company received formal notification on May 20, 2026 that it has not regained compliance with the Net Income Requirement, and a Nasdaq Hearings Panel will consider both deficiencies in deciding whether to suspend/delist the company's common shares. The filing explicitly states "there can be no assurance that the Company will be able to regain compliance or maintain its listing on Nasdaq," indicating imminent delisting risk.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-22
Item 3.01
Atlantic American Corporation received a formal notice from Nasdaq on May 21, 2026, stating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q and Form 10-K. The company has until June 16, 2026 to submit a compliance plan, with potential delisting consequences if the plan is not accepted. This is a direct delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-22
Item 3.01
Tempest Therapeutics received a deficiency letter from Nasdaq on May 19, 2026, notifying the company it failed to meet the minimum stockholders' equity requirement of $2.5 million (the company reported only $822,000 as of March 31, 2026). Additionally, on May 22, 2026, the company received notice of non-compliance with multiple Nasdaq board composition rules due to director resignations. The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within the extended 180-day cure period. This is a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-22
Item 3.01
All In FutureTech Alliance received a deficiency letter from Nasdaq on May 19, 2026, notifying it of non-compliance with Nasdaq Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for Q1 2026 and continued delinquency in filing its 2025 Form 10-K. The letter explicitly identifies these filing failures as bases for potential delisting.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-22
Item 3.01
Envoy Medical received a Nasdaq staff determination on November 19, 2025, that its Class A Common Stock failed to comply with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Although the company was granted an initial 180-day compliance period (until May 18, 2026) and subsequently a second 180-day period (until November 16, 2026), the filing explicitly discloses the failure to satisfy a continued listing rule and the delisting risk, which is the core substance of Item 3.01. This is material to investors as it directly threatens the company's continued listing on Nasdaq.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-22
Item 3.01
Terra Innovatum Global N.V. received a deficiency notice from Nasdaq on May 19, 2026, for failure to comply with Nasdaq Listing Rule 5250(c)(1) due to delinquent filings of its Form 10-Q and Form 10-K. While the notice has no immediate effect on listing, the company has until June 15, 2026, to submit a compliance plan and until October 12, 2026, to regain compliance, creating material delisting risk. This is a classic Item 3.01 disclosure of failure to satisfy continued listing standards.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-22
Item 3.01
Tenon Medical received a written notice from Nasdaq on May 21, 2026, stating it no longer complies with the minimum stockholders' equity requirement of $2,500,000 under Nasdaq Listing Rule 5550(b)(1), having reported only $1,895,000 in stockholders' equity as of March 31, 2026. The company has 45 days to submit a compliance plan or face delisting, with no assurance of success. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 97%
filed 2026-05-22
Item 3.01
La Rosa Holdings received a notice from Nasdaq on May 21, 2026, that the Company does not comply with Nasdaq Listing Rule 5250(c)(1) due to delinquent filings of its Form 10-Q and Form 10-K. The Company has until June 15, 2026, to submit a compliance plan, with Nasdaq discretion to grant up to 180 days from the Form 10-K due date to regain compliance.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-22
Item 3.01 discloses that GT Biopharma received notice from Nasdaq on May 20, 2026, granting an additional 180-day compliance period (until November 16, 2026) to regain compliance with the minimum bid price requirement of $1.00 per share. The company's stock had previously fallen below this threshold for 30 consecutive business days. This is a classic delisting risk disclosure—the company faces potential removal from Nasdaq if it cannot restore its stock price above $1.00 within the extended cure period.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-22
Ensysce Biosciences received notice from Nasdaq on May 21, 2026, that it is subject to delisting due to non-compliance with the $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan or face delisting, with a potential 180-day extension if the plan is accepted. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-22
The filing discloses a Nasdaq notice of non-compliance with Listing Rule 5250(c)(1) due to failure to timely file the Form 10-Q for the period ended March 31, 2026. While the notice has no immediate effect on listing, the company has 60 calendar days to submit a compliance plan or face potential delisting. This is a material disclosure of delisting risk under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-22
Laser Photonics received a notice from Nasdaq on May 21, 2026, stating non-compliance with continued listing rules due to failure to file the Form 10-Q for the period ended March 31, 2026. The company has 60 days to submit a compliance plan, with a maximum 180-day cure period ending November 16, 2026. This is a direct delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-22
The filing discloses a delinquency compliance alert from Nasdaq on May 21, 2026, advising that Global Interactive Technologies is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for Q1 2026 and its Form 10-K for 2025. The company has until October 12, 2026 to regain compliance, with a required update to its compliance plan by June 22, 2026. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-22
Item 3.01
RCI Hospitality received a written notice from Nasdaq on May 20, 2026 indicating non-compliance with Listing Rule 5250(c)(1) due to failure to file the Form 10-Q for Q1 2026. The company has until July 20, 2026 to submit a compliance plan and until November 16, 2026 to regain compliance by filing the overdue Form 10-Q. This is a classic delisting risk disclosure under Item 3.01, as it notifies investors of a failure to satisfy continued listing standards and the potential consequences if compliance is not restored.
View raw filing on EDGAR →
Delisting risk
confidence 94%
filed 2026-05-22
Item 3.01
Anavex received a delinquency notification from Nasdaq on May 20, 2026, for failure to timely file its Form 10-Q, triggering non-compliance with Nasdaq Listing Rule 5250(c)(1). The company has until July 20, 2026, to submit a compliance plan and until November 16, 2026, to regain compliance, or face potential delisting proceedings.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-21
Item 3.01
Hub Group received a notice from Nasdaq on May 19, 2026 that it failed to comply with Listing Rule 5250(c)(1) by not timely filing its Q1 2026 Form 10-Q. The company has been granted until June 3, 2026 to submit a compliance plan and until September 14, 2026 to file delinquent reports, with potential delisting if compliance is not regained within the prescribed timeframe.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-21
Item 8.01
The Company disclosed receipt of a Nasdaq notice on March 17, 2026 that it had failed to maintain the minimum market value of listed securities ($50 million) required under Nasdaq Listing Rule 5450(b)(2)(A). Although the Company subsequently regained compliance by May 20, 2026 based on stockholders' equity meeting Rule 5450(b)(1)(A), the disclosure centers on a delisting risk event—the failure to satisfy a continued listing rule and the subsequent resolution. This is material to investors as it directly affects the Company's ability to remain listed on Nasdaq.
View raw filing on EDGAR →
Delisting risk
confidence 92%
filed 2026-05-21
Item 8.01
The filing discloses that VenHub Global has regained compliance with Nasdaq Listing Rule 5450(a)(1) after the closing bid price of its Common Stock remained at $1.00 or greater for 10 consecutive business days. This directly addresses a delisting risk — the company was previously non-compliant with the minimum bid price rule and has now cured that deficiency. The materiality is high because delisting risk materially affects investor assessment of the registrant's continued market access and trading liquidity.
View raw filing on EDGAR →
Delisting risk
confidence 85%
filed 2026-05-21
Item 8.01
The filing discloses a delisting risk event: Aterian received a Nasdaq notice on December 9, 2025 that it failed to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2), triggering a 180-day cure period. Although the company subsequently regained compliance by May 19, 2026, the core event disclosed is the delisting notice and the company's status relative to continued listing standards. This is material to investors as it directly affects the registrant's exchange listing status.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-21
The filing discloses that Algorhythm Holdings received a Nasdaq delisting notice on November 28, 2025 for failing to maintain the required $2.5 million stockholders' equity under Listing Rule 5550(b)(1), and while the company claims to have regained compliance as of March 31, 2026, Nasdaq explicitly warned that "if at the time of its next periodic report the Company does not evidence compliance, the Company may be subject to delisting." This is a material delisting risk disclosure under Item 8.01.
View raw filing on EDGAR →
Delisting risk
confidence 97%
filed 2026-05-21
Item 3.01
The Company received a written notice from NYSE American on May 15, 2026, indicating non-compliance with continued listing standards due to a stockholders' deficit of approximately $1.4 million (against a required minimum of $2.0 million) and losses in three consecutive fiscal years. The Company must submit a compliance plan by June 7, 2026, or face delisting procedures by November 8, 2027.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-20
Socket Mobile received a Nasdaq deficiency notice on May 19, 2026 (Item 3.01) stating the company failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days, triggering a 180-day cure period ending November 16, 2026. The filing explicitly warns that failure to regain compliance could result in delisting, which would materially impair the company's ability to trade, raise capital, and maintain market value. This is a classic delisting-risk disclosure.
View raw filing on EDGAR →
Delisting risk
confidence 92%
filed 2026-05-20
Item 3.01
The Company notified NYSE on May 20, 2026 of non-compliance with continued listing rules: the resignation of Jared Roscoe from the board resulted in the audit committee falling below the minimum two independent directors required under NYSE Listed Company Manual Section 303A.07(a).
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-20
Item 3.01
The filing discloses that Singularity Future Technology Ltd. received a Nasdaq staff determination notice on November 19, 2025, for failure to maintain the $1 minimum bid price required under Nasdaq Listing Rule 5550(a)(2). The Company was initially granted a 180-day compliance period (until May 18, 2026) and subsequently granted a second 180-day compliance period (until November 16, 2026). The disclosure explicitly states that if the Company does not regain compliance by the Compliance Date, Nasdaq will provide written notification that the Company's securities are subject to delisting. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 85%
filed 2026-05-20
Item 8.01
The Company disclosed that it will not file its Q1 2026 Form 10-Q within the Rule 12b-25 extension period and anticipates receiving a notice of non-compliance from Nasdaq under Listing Rule 5250(c)(1) due to the late filing. While the Company expects a grace period to regain compliance, the anticipated non-compliance with continued listing rules creates delisting risk.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-20
Item 3.01
The filing discloses that Nasdaq notified the Company on May 14, 2026 of its determination to delist the Company's common stock pursuant to Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the Company's Chapter 11 bankruptcy filing. Trading will be suspended on May 21, 2026, and a Form 25-NSE will be filed to remove the Common Stock from listing and registration on Nasdaq. This is a material delisting event that directly affects the registrant's public market access.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-20
The filing discloses that on May 19, 2026, Aimei Health Technology received a notice from Nasdaq's Listing Qualifications Department stating the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for the quarter ended March 31, 2026. The notice explicitly states that if the Company fails to regain compliance, "the Company's securities will be subject to delisting from Nasdaq." This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-20
Item 3.01
The Company received formal notice from Nasdaq on May 19, 2026, that its Common Stock will be delisted from The Nasdaq Capital Market due to failure to regain compliance with the minimum bid price requirement ($1.00 per share) and stockholders' equity requirement ($2.5 million). This is a definitive delisting notice, not merely a warning or compliance period, making it a material event that directly affects the registrant's listing status and investor access to the security.
View raw filing on EDGAR →
Delisting risk
confidence 92%
filed 2026-05-20
Item 3.01
The filing discloses a failure to satisfy Nasdaq Listing Rule 5605(c)(2)(A) following Daniel Hennessy's resignation from the Audit Committee, which reduced the committee below the required three independent members. Although the Company subsequently regained compliance on May 15, 2026 through Bruce Brown's appointment and Nasdaq confirmed restoration of compliance on May 19, 2026, the Item 3.01 disclosure itself documents the delisting risk event and its resolution. This is material to investors as it reflects governance compliance issues and potential listing jeopardy.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-19
Item 3.01
On May 19, 2026, Mister Car Wash notified NASDAQ of the merger consummation and requested delisting of its common stock (ticker 'MCW') via Form 25 filing. Trading was suspended prior to market open, and the company intends to file Form 15 to deregister and terminate reporting obligations.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-19
Item 3.01
The filing discloses that Nasdaq has notified Bitcoin Depot that trading of its Class A common stock and warrants will be suspended effective May 26, 2026, and a Form 25-NSE will be filed to remove the securities from listing and registration on Nasdaq. This is a direct delisting notice triggered by the company's Chapter 11 bankruptcy filing and failure to timely file its Form 10-Q, making this a clear delisting_risk event under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-19
Item 8.01
MSP Recovery received notice from OTC Markets that its Class A common stock will be downgraded from the OTCQB Venture Market to the OTC Pink market effective May 20, 2026, due to failure to timely file its Form 10-K and OTCQB Annual Certification. The downgrade could adversely affect liquidity, market price, analyst coverage, and investor access.
View raw filing on EDGAR →